BTDPY vs LGND
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BTDPY · BARRATT REDROW PLC UNSP ADR EA REPR 2 ORD SHARES$8.05 ▼ 4.16%
LGND · Ligand Pharmaceuticals$286.85 ▼ 0.03%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BTDPY -17.9%
- LGND +38.6%
Head to head
| Metric | BTDPY | LGND |
|---|---|---|
| Price | $8.05 | $286.85 |
| Change today | ▼ 4.16% | ▼ 0.03% |
| Market cap | $5.74B | $5.74B |
| Return, 3 months | -5.5% | +2.4% |
| Return, year to date | -22.1% | +51.7% |
| Return, 1 year | -18.1% | +44.0% |
| P/E (TTM) | 17.9 | 115.2 |
| P/B | 0.5 | 6.0 |
| P/E percentile vs own 5y | – | 99th |
| Dividend yield | 1.98% | – |
| Revenue growth (YoY, latest qtr) | – | -31.8% |
| Net profit growth (YoY) | – | -124.3% |
| Gross margin | – | 95.2% |
| Operating margin | – | 14.4% |
| Net margin | – | 20.3% |
| Return on equity | – | 5.4% |
| Analyst target vs. price | – | +27.9% |
| Analyst buy share | – | 100% |
| RSI (14) | 40 | 39 |
| 30-day volatility | 39.6% | 38.6% |
| Max drawdown, 1 year | -41.1% | -14.7% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LGND is the largest of the group by market value.
- LGND has returned the most over the past year.
- BTDPY carries the lowest trailing P/E.
- LGND has been the calmest stock over the last 30 days.